Now showing items 1-6 of 6

    • CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. 

      Shenoy, TR; Boysen, G; Wang, MY; Xu, QZ; Guo, W; Koh, FM; Wang, C; Zhang, LZ; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, DN; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, DY; de Bono, J; Wu, H (2017-07)
      Background:Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized ...
    • Clinical development of new drug-radiotherapy combinations. 

      Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)
      In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...
    • Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. 

      Andreassen, CN; Rosenstein, BS; Kerns, SL; Ostrer, H; De Ruysscher, D; Cesaretti, JA; Barnett, GC; Dunning, AM; Dorling, L; West, CML; Burnet, NG; Elliott, R; Coles, C; Hall, E; Fachal, L; Vega, A; Gómez-Caamaño, A; Talbot, CJ; Symonds, RP; De Ruyck, K; Thierens, H; Ost, P; Chang-Claude, J; Seibold, P; Popanda, O; Overgaard, M; Dearnaley, D; Sydes, MR; Azria, D; Koch, CA; Parliament, M; Blackshaw, M; Sia, M; Fuentes-Raspall, MJ; Ramon Y Cajal, T; Barnadas, A; Vesprini, D; Gutiérrez-Enríquez, S; Mollà, M; Díez, O; Yarnold, JR; Overgaard, J; Bentzen, SM; Alsner, J; International Radiogenomics Consortium (RgC) (2016-12)
      Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a well-powered ...
    • Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. 

      Kerns, SL; Dorling, L; Fachal, L; Bentzen, S; Pharoah, PDP; Barnes, DR; Gómez-Caamaño, A; Carballo, AM; Dearnaley, DP; Peleteiro, P; Gulliford, SL; Hall, E; Michailidou, K; Carracedo, Á; Sia, M; Stock, R; Stone, NN; Sydes, MR; Tyrer, JP; Ahmed, S; Parliament, M; Ostrer, H; Rosenstein, BS; Vega, A; Burnet, NG; Dunning, AM; Barnett, GC; West, CML; Radiogenomics Consortium (2016-08)
      Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. ...
    • p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. 

      Yogev, O; Barker, K; Sikka, A; Almeida, GS; Hallsworth, A; Smith, LM; Jamin, Y; Ruddle, R; Koers, A; Webber, HT; Raynaud, FI; Popov, S; Jones, C; Petrie, K; Robinson, SP; Keun, HC; Chesler, L (2016-05)
      Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare ...
    • Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. 

      Martin, S; Sydenham, M; Haviland, J; A'Hern, R; Owen, R; Bliss, J; Yarnold, J (2010-10)
      To test for association between single nucleotide polymorphisms at the TGFβ1 locus and the risk of late normal tissue injury following whole breast radiotherapy.A retrospective study compared the number of variant alleles ...